ALMS · Alumis Inc. · Stock research

Current Thesis

Alumis is a clinical-stage immunology company whose entire equity story runs through one molecule: envudeucitinib (ESK-001), a next-generation, highly selective oral TYK2 inhibitor. The narrative accelerated hard on 2026-01-06 when Phase 3 psoriasis topline detonated the stock +95.31% in a single session, and it has since ground from a sub-$10 pre-catalyst base to ~$28. The psoriasis leg is now largely de-risked full ONWARD1/ONWARD2 data (2026-03-28) showed PASI 90 of 68.0% and 62.1% and PASI 100 of 41.0% and 39.5% at Week 24, cross-trial the leading skin clearance among next-gen oral therapies. What an investor is actually buying at this price is the next binary: the LUMUS Phase 2b topline in systemic lupus (SLE) due Q3 2026. Lupus is a far larger, higher-value, and historically brutal indication; a clean hit re-rates the platform beyond dermatology, a miss caps the name as one more oral psoriasis pill in a crowded field. This is a binary-catalyst setup, not a trend-follow.

Bullish and bearish views on Alumis Inc.

The model's bull view on Alumis Inc. (ALMS), in brief: Best-in-class Phase 3 efficacy, dated 2026-03-28: PASI 90 68.0%/62.1% and PASI 100 41.0%/39.5% at Week 24 across 1,700+ patients in ONWARD1/ONWARD2; management frames this as leading skin clearance versus next-gen oral peers including the entrenched incumbent Sotyktu. The bear view: Crowded oral autoimmune field: Sotyktu (BMS deucravacitinib) is the established oral TYK2, and Takeda's zasocitinib (next-gen TYK2) is also advancing cross-trial efficacy edges do not guarantee formulary share or pricing. Both cases follow in full.

Bull Case

• Best-in-class Phase 3 efficacy, dated 2026-03-28: PASI 90 68.0%/62.1% and PASI 100 41.0%/39.5% at Week 24 across 1,700+ patients in ONWARD1/ONWARD2; management frames this as leading skin clearance versus next-gen oral peers including the entrenched incumbent Sotyktu.
• Narrative velocity is proven, not theoretical: the 2026-01-06 topline (PASI 75 74%, sPGA 0/1 59% at Week 16) produced a +95.31% single-day move the market demonstrably pays up for this readout profile.
• Asymmetric lupus optionality: LUMUS Phase 2b SLE topline anticipated Q3 2026. TYK2 sits directly on the type-I interferon axis central to lupus biology; a positive read opens a multi-billion-dollar indication that no oral TYK2 has cracked.
• Funded through both catalysts: $569.5M cash and marketable securities at 2026-03-31, runway stated through Q4 2027 covers the Q4 2026 psoriasis NDA and the lupus readout without a forced raise.
• Sell-side still catching up: consensus Buy, median PT ~$38.50 versus ~$28 spot; Wells Fargo OW $51, Morgan Stanley OW $39, Guggenheim Buy $34 targets were being raised through June, the signature of a narrative sell-side hasn't fully priced.
• De-risking event on the calendar: psoriasis NDA submission targeted Q4 2026 converts a clinical asset toward a commercial one.

Bear Case

• Crowded oral autoimmune field: Sotyktu (BMS deucravacitinib) is the established oral TYK2, and Takeda's zasocitinib (next-gen TYK2) is also advancing cross-trial efficacy edges do not guarantee formulary share or pricing.
• Pure cash-burn profile: Q1 2026 (reported 2026-05-14) showed net loss of $93.1M and revenue collapsing to $1.7M from $17.4M a year prior; no meaningful product revenue before 2027 at the earliest.
• Priced near the top of its range: ~$28.31 against a 52-week range of $3.25–$31.35 the stock has 8x'd off the lows, so a great deal of good news is embedded before the lupus print.
• LUMUS is Phase 2b in the hardest indication: SLE is the immunology graveyard; a primary-endpoint miss could round-trip a large slice of the post-January gains.
• Serial equity issuance into strength: a $17.00 offering (20.3M shares) closed 2026-01-09 and $345.1M gross was raised around the March results management taps the market when the tape is strong.
• Merger overhang: the ACELYRIN combination (closed 2025-05-21, $238.1M, 48.65M shares issued) leaves a reverse-merger-flavored share base and integration risk.
• Category regulatory shadow: JAK/TYK2 class carries boxed-warning history (cardiovascular, malignancy) that colors the FDA path for every oral entrant.

Setup & Price Structure

Spot ~$28.31 at the 2026-07-10 close (−6.57% that session; ~$28.50 after-hours), against a 52-week range of $3.25–$31.35 and a market cap near $3.6B. Structurally the name went vertical on the 2026-01-06 topline, absorbed the $17.00 secondary two sessions later, then built a rising base roughly $20.81 in April, up through the $20–23 consolidation shelf into May, and out to the high-$20s by July. Price is now in the top decile of its 52-week range, only ~10% under the $31.35 high, and pushing into an undated Phase 2b binary. That is the running-into-the-catalyst stance: elevated implied volatility, real gap risk in both directions, and thin margin for error on a fresh entry near the highs. The rising base built between April and June is the structure that matters losing it says the pre-readout momentum leg is over.

Catalyst Calendar (next 30 days)

• LUMUS Phase 2b SLE topline Q3 2026 (est. ~2026-09-15, not date-certain; could land anywhere in the quarter). The defining binary. No confirmed day inside the next 30 days as of 2026-07-11, but the window is open and headline risk is live.
• Two-year Phase 2 long-term safety data H2 2026. Supports the NDA and the durability narrative.
• Envudeucitinib psoriasis NDA submission Q4 2026 (est. ~2026-11). Converts the de-risked leg toward commercialization.
• No dated, confirmed event strictly within the next 30 days; LUMUS is the standing watch item and can surprise on timing.

What Would Change Our Mind

• A weekly close below $22 breaks the April–June rising base that carried the stock from ~$20 to ~$28 and signals the pre-readout momentum leg has failed.
• LUMUS lupus Phase 2b missing its primary endpoint the platform premium evaporates and the name re-rates to a psoriasis-only oral in a crowded category.
• A theme flip in oral autoimmune sentiment a competitor (Takeda zasocitinib, BMS) posting superior data or an FDA class-safety action that reprices the whole TYK2 group.
• A pre-readout equity raise, which would confirm management is again selling into strength and dilute the lupus optionality.

Correlation Notes

ALMS is an idiosyncratic single-catalyst biotech; its beta to the broad market runs mostly through XBI-style small-cap risk appetite and rate sensitivity rather than any sector fundamental. Direct read-across names: Bristol-Myers Squibb (Sotyktu, the incumbent oral TYK2 benchmark every ONWARD number is measured against) and Takeda's zasocitinib program (the other next-gen oral TYK2 in late-stage development — competitive data from either reprices Alumis). Broader oral-autoimmune comps include AbbVie (Rinvoq) and the JAK complex, which set the class regulatory tone. The lupus readout is a company-specific event with near-zero index correlation it will move on its own data, and on the day the tape won't matter.